SG11202008620VA - Humanized rodents for testing therapeutic agents - Google Patents

Humanized rodents for testing therapeutic agents

Info

Publication number
SG11202008620VA
SG11202008620VA SG11202008620VA SG11202008620VA SG11202008620VA SG 11202008620V A SG11202008620V A SG 11202008620VA SG 11202008620V A SG11202008620V A SG 11202008620VA SG 11202008620V A SG11202008620V A SG 11202008620VA SG 11202008620V A SG11202008620V A SG 11202008620VA
Authority
SG
Singapore
Prior art keywords
therapeutic agents
testing therapeutic
humanized rodents
rodents
humanized
Prior art date
Application number
SG11202008620VA
Other languages
English (en)
Inventor
Vera Voronina
Corey Momont
John Mcwhirter
Naxin Tu
Lynn Macdonald
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11202008620VA publication Critical patent/SG11202008620VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202008620VA 2018-03-26 2019-03-25 Humanized rodents for testing therapeutic agents SG11202008620VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862648197P 2018-03-26 2018-03-26
US201862689628P 2018-06-25 2018-06-25
PCT/US2019/023899 WO2019190990A1 (en) 2018-03-26 2019-03-25 Humanized rodents for testing therapeutic agents

Publications (1)

Publication Number Publication Date
SG11202008620VA true SG11202008620VA (en) 2020-10-29

Family

ID=66041822

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202008620VA SG11202008620VA (en) 2018-03-26 2019-03-25 Humanized rodents for testing therapeutic agents

Country Status (12)

Country Link
US (2) US11576984B2 (he)
EP (1) EP3772926A1 (he)
JP (2) JP7328243B2 (he)
KR (1) KR20210004994A (he)
CN (2) CN116420679A (he)
AU (1) AU2019242586A1 (he)
CA (1) CA3093850A1 (he)
IL (1) IL277355A (he)
MA (1) MA52177A (he)
SG (1) SG11202008620VA (he)
TW (1) TWI829679B (he)
WO (1) WO2019190990A1 (he)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018338790B2 (en) 2017-09-29 2022-09-15 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized TTR locus and methods of use
SG11202002456WA (en) 2017-11-30 2020-04-29 Regeneron Pharma Non-human animals comprising a humanized trkb locus
AU2019242586A1 (en) 2018-03-26 2020-10-01 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
WO2020018511A1 (en) 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Non-human animal models of ditra disease and uses thereof
CN113473850A (zh) 2019-02-22 2021-10-01 瑞泽恩制药公司 具有遗传修饰的钠通道的啮齿动物及其使用方法
SG11202108454RA (en) 2019-04-04 2021-09-29 Regeneron Pharma Non-human animals comprising a humanized coagulation factor 12 locus
KR20220016869A (ko) 2019-06-04 2022-02-10 리제너론 파마슈티칼스 인코포레이티드 베타-슬립 돌연변이를 갖는 인간화 ttr 좌위를 포함하는 비-인간 동물 및 사용 방법
MX2021015122A (es) 2019-06-07 2022-04-06 Regeneron Pharma Animales no humanos que comprenden un locus de albumina humanizado.
EP4262373A1 (en) 2020-12-16 2023-10-25 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
WO1989011490A1 (en) 1988-05-27 1989-11-30 Schering Biotech Corporation HUMAN Fcgamma RECEPTOR III
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5258359A (en) 1991-08-02 1993-11-02 Monsanto Company Glyphosant-containing herbicidal compositions comprising acetylenic diol rainfastness enhancing agents
WO1994006908A1 (en) 1992-09-11 1994-03-31 The Regents Of The University Of California Transgenic non-human animals having targeted lymphocyte transduction genes
US5877396A (en) 1993-04-23 1999-03-02 Sloan Kettering Institute For Cancer Research Mice mutant for functional Fc receptors and method of treating autoimmune diseases
US6111166A (en) 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP1978033A3 (en) * 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6676927B1 (en) 1999-01-20 2004-01-13 The Rockefeller University Animal model and methods for its use in the selection of cytotoxic antibodies
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
JP3597140B2 (ja) * 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
WO2002006633A1 (en) 2000-07-18 2002-01-24 The Charles Machine Works, Inc. Remote control for a drilling machine
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2002043658A2 (en) 2000-11-06 2002-06-06 The Jackson Laboratory Fcrn-based therapeutics for the treatment of auto-immune disorders
ATE488576T1 (de) 2001-02-20 2010-12-15 Univ Georgia Schnellproduktion monoklonaler antikörper
FR2822161B1 (fr) 2001-03-15 2003-09-19 Genoway Cellule et animal transgenique modelisant les reponses humaines allergiques mediees par les ige, et leurs utilisations
JP4653915B2 (ja) 2001-10-29 2011-03-16 独立行政法人科学技術振興機構 全身性エリテマトーデスモデル非ヒト動物
US7737260B2 (en) * 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Protein complex using an immunoglobulin fragment and method for the preparation thereof
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20090042291A1 (en) 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
CA2488775C (en) 2002-06-07 2011-04-12 Arthron Limited Fcyriia transgenic animal model for autoimmune disease
JP2004147535A (ja) 2002-10-29 2004-05-27 Japan Science & Technology Agency ギラン・バレー症候群及び／又はフィッシャー症候群発症モデル非ヒト動物
DE60322426D1 (he) 2002-12-16 2008-09-04 Genentech Inc
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
US8218805B2 (en) 2003-10-11 2012-07-10 Charles Hornback Wireless speaker system for use with ceiling fans
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
MXPA06010673A (es) * 2004-03-19 2007-06-20 Amgen Inc Reduccion del riesgo de anticuerpos humanos anti-humano a traves de manipulacion del gen v.
EP2295588B1 (en) 2004-05-27 2018-03-07 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses thefor
DK2767161T3 (en) 2004-10-19 2018-05-07 Regeneron Pharma Method of generating an animal homozygous for genetic modification
WO2007024249A2 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
US20060222653A1 (en) 2004-11-12 2006-10-05 Xencor, Inc. Antibodies operably linked to selected chemoattractants
WO2006076594A2 (en) 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
JP2009504787A (ja) 2005-08-19 2009-02-05 シーラス コーポレイション 抗体によって媒介される免疫応答の増強
EP1999470A4 (en) 2006-03-10 2009-08-19 Macrogenics Inc IDENTIFICATION AND GENETIC MODIFICATION OF ANTIBODIES WITH HEAVY CHAINS OF VARIANTS AND METHODS OF USE THEREOF
WO2007117410A2 (en) 2006-03-31 2007-10-18 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
US20080003225A1 (en) 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
WO2008028068A2 (en) * 2006-08-30 2008-03-06 Genentech, Inc. NON-HUMAN PRIMATE FCεR1α POLYPEPTIDES
US20090053210A1 (en) 2006-09-01 2009-02-26 Roland Buelow Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
PE20081216A1 (es) 2006-09-01 2008-09-04 Therapeutic Human Polyclonals Inc Expresion mejorada de la inmunoglobulina humana o humanizada en animales transgenicos no humanos
US8042033B2 (en) 2006-11-29 2011-10-18 Lg Electronics Inc. Protection of access information in wireless communications
JP5299902B2 (ja) 2007-01-30 2013-09-25 中外製薬株式会社 キメラＦｃγレセプター及び該レセプターを用いたＡＤＣＣ活性測定方法
US7816082B2 (en) 2007-03-06 2010-10-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of identifying pancreatic cancer cells
NO2195023T3 (he) * 2007-08-29 2018-08-04
AU2008335178A1 (en) 2007-12-10 2009-06-18 Ablexis Llc Methods for sequential replacement of targeted region by homologous recombination
EP2623112B1 (en) 2008-06-27 2015-03-04 Zymogenetics, Inc. Soluble hybrid Fc gamma receptors and related methods
WO2010010549A2 (en) 2008-07-23 2010-01-28 Rappaport Family Institute For Research In The Medical Sciences Methods of altering peripheral b cell populations and uses thereof
GB0909906D0 (en) * 2009-06-09 2009-07-22 Affitech As Antibodies
US9445581B2 (en) * 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
JP5796846B2 (ja) 2009-11-17 2015-10-21 エスエービー エルエルシー ヒト人工染色体ベクター
LT2954779T (lt) * 2009-12-10 2019-05-27 Regeneron Pharmaceuticals, Inc. Pelės, gaminančios sunkiosios grandinės antikūnus
US8883496B2 (en) 2009-12-21 2014-11-11 Regeneron Phamaceuticals, Inc. Humanized FcgR mice
SG181690A1 (en) 2009-12-21 2012-07-30 Regeneron Pharma Humanized fcy r mice
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
EP2552957A4 (en) 2010-03-29 2013-11-20 Zymeworks Inc ANTIBODIES HAVING ENHANCED OR DELETED EFFECTIVE FUNCTION
TWI667346B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
CN103228130B (zh) 2010-06-17 2016-03-16 科马布有限公司 动物模型及治疗分子
IL300712A (he) 2010-06-22 2023-04-01 Regeneron Pharma עכברים עם שרשרת קלה למדא אנושית
DK2601298T3 (en) 2010-08-02 2017-02-27 Regeneron Pharma Mice generating binding proteins comprising VL domains
PL2550363T3 (pl) 2011-02-25 2015-05-29 Regeneron Pharma Myszy adam6
JP5893258B2 (ja) 2011-03-31 2016-03-23 フェリカネットワークス株式会社 情報処理装置および方法、並びにプログラム
EP3216871B1 (en) 2011-10-17 2021-12-22 Regeneron Pharmaceuticals, Inc. Restricted immunoglobulin heavy chain mice
RS56656B1 (sr) 2011-10-28 2018-03-30 Regeneron Pharma Miševi sa genetski modifikovanim glavnim kompleksom gena tkivne podudarnosti
CA2852962C (en) 2011-10-28 2022-05-03 Regeneron Pharmaceuticals, Inc. Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
EP2818478B1 (en) 2011-10-28 2017-02-01 Regeneron Pharmaceuticals, Inc. Humanized IL-6 and IL-6 receptor
PT2773671T (pt) 2011-11-04 2021-12-14 Zymeworks Inc Geração de anticorpo heterodimérico estável com mutações no domínio fc
US9301510B2 (en) 2012-03-16 2016-04-05 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with pH-dependent binding characteristics
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
EP2883449B1 (en) 2012-03-16 2018-02-07 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
BR112014022855A2 (pt) 2012-03-16 2017-07-18 Regeneron Pharma animal não humano geneticamente modificado, mamífero geneticamente modificado, e, método para fabricar um animal não humano
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
WO2013144567A1 (en) * 2012-03-28 2013-10-03 Kymab Limited Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
JP5920830B2 (ja) 2012-09-28 2016-05-18 シスメックス株式会社 試料調製装置および細胞分析装置
MX370856B (es) 2012-11-05 2020-01-08 Regeneron Pharma Animales no humanos geneticamente modificados y metodos de uso de los mismos.
KR102579405B1 (ko) 2013-02-20 2023-09-18 리제너론 파아마슈티컬스, 인크. 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
DK2840892T3 (en) 2013-02-20 2018-07-23 Regeneron Pharma Non-human animals with modified heavy chain immunoglobulin sequences
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
KR102211267B1 (ko) 2013-02-22 2021-02-04 리제너론 파아마슈티컬스, 인크. 사람화된 주요 조직적합성 복합체를 발현하는 마우스
JP6411463B2 (ja) 2013-04-16 2018-10-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ラットゲノムの標的改変
EP2837637A1 (en) * 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
LT3175706T (lt) 2013-09-23 2019-02-25 Regeneron Pharmaceuticals, Inc. Gyvūnai, išskyrus žmogų, turintys humanizuotą signalą reguliuojančio baltymo geną
AU2014353346B2 (en) 2013-11-19 2020-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized B-cell activating factor gene
RU2685914C1 (ru) 2013-12-11 2019-04-23 Регенерон Фармасьютикалс, Инк. Способы и композиции для направленной модификации генома
JP6267986B2 (ja) * 2014-02-13 2018-01-24 株式会社特殊免疫研究所 ヒトの特定分子と結合する分子標的物質のｉｎｖｉｖｏ評価法
KR102223264B1 (ko) 2014-04-08 2021-03-09 리제너론 파아마슈티컬스, 인크. 인간화된 Fc-감마 수용체를 갖는 비-인간 동물
NO2785538T3 (he) 2014-05-07 2018-08-04
SG10202002187WA (en) 2014-05-19 2020-04-29 Regeneron Pharma Genetically modified non-human animals expressing human epo
PL3152312T3 (pl) 2014-06-06 2020-08-10 Regeneron Pharmaceuticals, Inc. Sposoby i kompozycje do modyfikowania docelowego locus
MX2016016903A (es) 2014-06-19 2017-03-27 Regeneron Pharma Animales no humanos que tienen un gen de muerte celular programada 1 humanizado.
PT3155099T (pt) 2014-06-23 2018-04-20 Regeneron Pharma Montagem de dna mediada por nuclease
SI3223605T1 (sl) 2014-11-24 2021-03-31 Regeneron Pharmaceuticals, Inc. Nehumane živali, ki izražajo humaniziran CD3 kompleks
NZ731471A (en) * 2014-12-05 2021-12-24 Regeneron Pharma Non-human animals having a humanized cluster of differentiation 47 gene
US9913461B2 (en) 2014-12-09 2018-03-13 Regeneron Pharmaceuticals, Inc. Genetically modified mouse whose genome comprises a humanized CD274 gene
MX2017012829A (es) 2015-04-06 2018-02-23 Regeneron Pharma Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos.
WO2016175285A1 (ja) * 2015-04-30 2016-11-03 株式会社特殊免疫研究所 ヒト特定分子およびヒトＦｃγ受容体ファミリーを発現するトランスジェニック非ヒト動物
EP3297430A4 (en) * 2015-05-22 2019-01-23 Champions Oncology, Inc. HUMANIZED MOUSE AND USES THEREOF
CN107709550A (zh) * 2015-06-18 2018-02-16 转基因股份有限公司 脏器人源化小鼠
WO2017010423A1 (ja) * 2015-07-10 2017-01-19 中外製薬株式会社 内因性ｃｄ３遺伝子をヒトｃｄ３遺伝子に置換した非ヒト動物
MX2018005389A (es) 2015-11-20 2018-09-05 Regeneron Pharma Animales no humanos que tienen un gen 3 de activacion linfocitaria humanizado.
EP3457840B1 (en) 2016-05-20 2024-04-10 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
DK3766343T3 (da) 2016-11-04 2022-06-20 Regeneron Pharma Ikke-humane dyr med et manipuleret immunoglobulin-lambda-letkædelocus
US11696572B2 (en) 2017-06-27 2023-07-11 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ASGR1 locus
SG11202002456WA (en) 2017-11-30 2020-04-29 Regeneron Pharma Non-human animals comprising a humanized trkb locus
AU2019242586A1 (en) 2018-03-26 2020-10-01 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents

Also Published As

Publication number Publication date
JP2023116487A (ja) 2023-08-22
JP2021519418A (ja) 2021-08-10
US20230277692A1 (en) 2023-09-07
CN116420679A (zh) 2023-07-14
CN112105260A (zh) 2020-12-18
WO2019190990A4 (en) 2020-01-02
JP7328243B2 (ja) 2023-08-16
WO2019190990A1 (en) 2019-10-03
CN112105260B (zh) 2023-04-28
RU2020133441A (ru) 2022-04-26
TWI829679B (zh) 2024-01-21
AU2019242586A1 (en) 2020-10-01
MA52177A (fr) 2021-02-17
US20190290783A1 (en) 2019-09-26
IL277355A (he) 2020-11-30
KR20210004994A (ko) 2021-01-13
CA3093850A1 (en) 2019-10-03
EP3772926A1 (en) 2021-02-17
US11576984B2 (en) 2023-02-14
TW202003852A (zh) 2020-01-16

Similar Documents

Publication Publication Date Title
IL277355A (he) מכרסמים מואנשים לבדיקת חומרים טיפוליים
GB201820166D0 (en) Therapeutic agents
IL281921A (he) בדיקת תוכנה
GB201820165D0 (en) Therapeutic agents
AU201816713S (en) Elongated skin toning device
GB201814169D0 (en) Blockchain autonoumous agents
ZA202104708B (en) Cleaning device for an application device
IL281449A (he) נוגדנים אנטי- ifnar1 לטיפול במחלות אוטואימוניות
GB201805816D0 (en) Therapeutic agents
PL3773144T3 (pl) Urządzenie okulistyczne
SG11202102139YA (en) Network methods for neurodegenerative diseases
IL279355A (he) חלבון קושר אנטיגן נגד steap1
EP3815744A4 (en) ANIMAL RADIOTHERAPY DEVICE
IL282675A (he) מכשיר חקלאי
GB2590058B (en) Animal related apparatus
GB2585661B (en) Radiotherapy device
GB2581986B (en) Animal footbath apparatus
GB2588082B (en) Rodent control device
GB2590457B (en) Radiotherapy device
GB201915655D0 (en) Rodent control device
GB201820162D0 (en) Therapeutic agents
GB201820172D0 (en) Therapeutic agents
GB201820160D0 (en) Therapeutic agents
GB201820170D0 (en) Therapeutic agents
GB201820164D0 (en) Therapeutic agents